PL2521562T3 - Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych - Google Patents

Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych

Info

Publication number
PL2521562T3
PL2521562T3 PL11700973T PL11700973T PL2521562T3 PL 2521562 T3 PL2521562 T3 PL 2521562T3 PL 11700973 T PL11700973 T PL 11700973T PL 11700973 T PL11700973 T PL 11700973T PL 2521562 T3 PL2521562 T3 PL 2521562T3
Authority
PL
Poland
Prior art keywords
treatment
respiratory tract
viral infections
infections
viral
Prior art date
Application number
PL11700973T
Other languages
English (en)
Inventor
Wynne Weston-Davies
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1000318.4A external-priority patent/GB201000318D0/en
Priority claimed from GBGB1005071.4A external-priority patent/GB201005071D0/en
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Publication of PL2521562T3 publication Critical patent/PL2521562T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
PL11700973T 2010-01-08 2011-01-10 Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych PL2521562T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1000318.4A GB201000318D0 (en) 2010-01-08 2010-01-08 Method of treatment
GBGB1005071.4A GB201005071D0 (en) 2010-03-25 2010-03-25 Method of treatment
EP11700973.8A EP2521562B1 (en) 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract
PCT/GB2011/000022 WO2011083317A1 (en) 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract

Publications (1)

Publication Number Publication Date
PL2521562T3 true PL2521562T3 (pl) 2020-04-30

Family

ID=44305222

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11700973T PL2521562T3 (pl) 2010-01-08 2011-01-10 Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych

Country Status (9)

Country Link
US (4) US20120283167A1 (pl)
EP (1) EP2521562B1 (pl)
JP (1) JP5840623B2 (pl)
CN (1) CN102762223B (pl)
AU (2) AU2011204483B2 (pl)
CA (1) CA2785612C (pl)
NZ (1) NZ601018A (pl)
PL (1) PL2521562T3 (pl)
WO (1) WO2011083317A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201607740TA (en) * 2014-03-20 2016-10-28 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2017283470B2 (en) 2016-06-14 2024-03-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies and uses thereof
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
EP3849588A1 (en) * 2018-09-10 2021-07-21 Volution Immuno Pharmaceuticals SA Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2020247610A1 (en) 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
EP4034237A1 (en) 2019-09-27 2022-08-03 Volution Immuno Pharmaceuticals SA Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230218571A1 (en) * 2020-04-01 2023-07-13 Thiogenesis Therapeutics, Inc. Cysteamine precursor compounds for the treatment of betacoronavirus infections
EP4146168A4 (en) * 2020-05-08 2024-06-12 Kodiak Sciences Inc. USE OF IL-6 ANTIBODIES AND VEGF TRAPS AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017099A1 (en) 1992-02-27 1993-09-02 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2004106369A2 (en) * 2003-06-02 2004-12-09 Evolutec Limited Complement inhibitors from ticks
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US7274999B1 (en) * 2006-03-10 2007-09-25 Atmel Corporation Brownout detector system and method
JP2009533428A (ja) * 2006-04-12 2009-09-17 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 筋肉内抗ウイルス処置
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment

Also Published As

Publication number Publication date
US20170065677A1 (en) 2017-03-09
US20200155646A1 (en) 2020-05-21
EP2521562A1 (en) 2012-11-14
WO2011083317A1 (en) 2011-07-14
US20120283167A1 (en) 2012-11-08
CA2785612A1 (en) 2011-07-14
US20150196619A1 (en) 2015-07-16
AU2011204483A1 (en) 2012-07-12
AU2016203058A1 (en) 2016-06-02
CN102762223A (zh) 2012-10-31
JP5840623B2 (ja) 2016-01-06
US9522171B2 (en) 2016-12-20
AU2011204483B2 (en) 2016-02-11
NZ601018A (en) 2013-09-27
CN102762223B (zh) 2014-09-03
EP2521562B1 (en) 2019-09-18
JP2013516450A (ja) 2013-05-13
AU2016203058B2 (en) 2018-01-18
CA2785612C (en) 2019-09-10

Similar Documents

Publication Publication Date Title
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
HUS2400017I1 (hu) Dolutegravir és lamivudin kombinációi HIV-fertõzés kezelésére
PL2627334T3 (pl) Kompozycje do stosowania w leczeniu zakażeń wirusowych
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
IL232046A (en) Furein derivatives for the treatment of viral infections
ZA201308746B (en) Quinazoline derivatives for the treatment of viral infections and further diseases
ZA201502238B (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IL222333A0 (en) Use of streptococcus salivarius in the treatment of chronic infections of the respiratory tract
GB201002243D0 (en) Respiratory disease treatment
PL2903608T3 (pl) Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
GB201002224D0 (en) Respiratory disease treatment
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
PT2544705T (pt) Interferão beta para uso no tratamento de doença do trato respiratório inferior causada por influenza
ZA201306342B (en) The treatment of viral infections
GB201012168D0 (en) Treatment of viral infections
GB201001821D0 (en) Treatment of viral infections
GB2477540A8 (en) Respiratory disease treatment
GB201001903D0 (en) Respiratory disease treatment
GB201002235D0 (en) Respiratory disease treatment
SI2315580T1 (sl) Farmacevtski pripravki in postopki za zdravljenjeinfekcij respiratornega trakta
GB0919711D0 (en) Treatment of viral infections
GB0913914D0 (en) Treatment of viral infections